Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

520 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2017-09-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to demonstrate the efficacy of Dysport for the improvement in appearance of moderate to severe glabellar lines and to assess the short term and long term safety of Dysport, used for the improvement in appearance of moderate to severe glabellar lines in Chinese subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

NCT05089357

Glabellar Lines

COMPLETED

DWP450 for Treating Moderate to Severe Glabellar Lines

NCT06354127

Moderate to Severe Glabellar Lines

COMPLETED PHASE3

A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

NCT06174688

Forehead Lines

COMPLETED PHASE3

A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

NCT06499688

Moderate to Severe Glabellar Lines

COMPLETED PHASE3

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

NCT00276315

Hemifacial Spasm

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The first treatment cycle will be double blind and subjects will be randomised to receive Dysport, Botox or placebo. After the first treatment cycle, all subjects will receive a maximum of four treatment cycles with Dysport, occurring at intervals of no less than 84 Days (12 weeks) between each treatment cycle, depending upon individual duration of response to Dysport treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glabellar Lines

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AbobotulinumtoxinA

Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.

Group Type EXPERIMENTAL

Botulinum toxin type A

Intervention Type BIOLOGICAL

OnabotulinumtoxinA

Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.

Group Type ACTIVE_COMPARATOR

Botulinum toxin type A

Intervention Type BIOLOGICAL

AbobotulinumtoxinA Placebo

Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

50 Units

OnabotulinumtoxinA Placebo

Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

20 Units

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Botulinum toxin type A

Intervention Type BIOLOGICAL

Botulinum toxin type A

Intervention Type BIOLOGICAL

Placebo

50 Units

Intervention Type DRUG

Placebo

20 Units

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AbobotulinumtoxinA (Dysport®) OnabotulinumtoxinA (Botox®)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of written informed consent
* Male or female Chinese subjects who are between 18 to 65 years of age inclusive.
* Have moderate or severe wrinkles of vertical glabellar lines (Grade 2 or 3) at maximum frown at baseline (Day 1), as assessed by the subject using SSA.
* Have moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at baseline (Day 1), as assessed by the Investigator using ILA.
* Be Botulinum Toxin (BTX) naïve or have received their most recent BTX-A treatment more than 1 year prior to screening.
* Have a negative pregnancy test
* Have an understanding of the study

Exclusion Criteria

* Any prior surgery affecting corrugator supercilii, prior blepharoplasty or brow lift, dermal resurfacing, or any prior cosmetic procedures or scars within 36 months.
* Any prior treatment with permanent fillers in the upper face.
* Any prior treatment with nonpermanent dermal fillers in the upper face within the past 3 years and/or skin abrasions/resurfacing, photorejuvenation or skin/vascular laser intervention within the past 12 months.
* Any planned facial cosmetic surgery or procedures during the study period.
* Lack of capacity to frown.
* Facial conditions that could affect safety or efficacy results.
* History of facial nerve palsy.
* Marked asymmetry; ptosis; excessive dermatochalasis; deep dermal scarring; thick sebaceous skin; photodamage etc.
* Presence of any condition that could affect the safety, conduct or outcome of the study.
* Any subjects who have any psychiatric illness or are taking antidepressant, anxiolytic or antipsychotic medication.
* Pregnant and/or lactating female subjects.
* Female subjects of childbearing potential not willing to use contraceptive measures throughout the course of the study.
* History of drug or alcohol abuse.
* Treatment with an experimental drug or device within 30 days prior to screening for this study and during the conduct of this study.
* Requirement for BTX injection to site(s) for disorders other than glabellar lines.
* Known allergy or hypersensitivity to BTX.
* Any medical condition or laboratory finding from central laboratory results.
* The subject is unable and/or unwilling to comply fully with the protocol and the study.
* Mental incapacity, unwillingness or language barriers.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No